Study shows promise in repairing damaged myelin
A scientific breakthrough provides new hope for millions of people living with multiple sclerosis. Researchers at OHSU have developed a compound that stimulates repair of the protective sheath that covers nerve cells in the brain and spinal cord.
The discovery, involving mice genetically engineered to mimic multiple sclerosis, published today in the journal JCI Insight.
MS is a chronic condition that affects an estimated 2.3 million people worldwide. In MS, the sheath covering nerve fibers in the brain and spinal cord becomes damaged, slowing or blocking electrical signals from reaching the eyes, muscles and other parts of the body. This sheath is called myelin. Although myelin can regrow through exposure to thyroid hormones, researchers have not pursued thyroid hormone therapies due to unacceptable side effects.
Although several treatments and medications alleviate the symptoms of MS, there is no cure.
“There are no drugs available today that will re-myelinate the de-myelinated axons and nerve fibers, and ours does that,” said senior author Tom Scanlan, Ph.D., professor of physiology and pharmacology in the OHSU School of Medicine.
Co-author Dennis Bourdette, M.D., chair of neurology in the OHSU School of Medicine and director of the OHSU Multiple Sclerosis Center, said he expects it will be a few years before the compound advances to the stage of a clinical trial involving people. Yet the discovery provides fresh hope for patients in Oregon and beyond.
“It could have a significant impact on patients debilitated by MS,” Bourdette said.
The discovery reported today, if ultimately proven in clinical trials involving people, appears to accomplish two important goals:
- Myelin repair with minimal side effects: The study demonstrated that the compound – known as sobetirome – promotes remylenation without the severe side effects of thyroid hormone therapy. Thyroid hormone therapy has not been tried in people because chronic elevated exposure known as hyperthyroidism harms the heart, bone, and skeletal muscle.
- Efficient delivery: Researchers developed a new derivative of sobetirome (Sob-AM2) that penetrates the blood brain barrier, enabling a tenfold increase in infiltration to the central nervous system.
“We’re taking advantage of the endogenous ability of thyroid hormone to repair myelin without the side effects,” said lead author Meredith Hartley, Ph.D., an OHSU postdoctoral researcher in physiology and pharmacology.
Co-authors credited the breakthrough to a collaboration that involved scientists and physicians with expertise ranging across neurology, genetics, advanced imaging, physiology and pharmacology.
Potential as a ‘total game-changer’
One patient said the research could be a “total game-changer” for people with MS.
Laura Wieden, 48, has lived with multiple sclerosis since being diagnosed in 1995. The daughter of Portland advertising executive Dan Wieden, she is the namesake and board member of the Laura Fund for Innovation in Multiple Sclerosis, which funded much of the research involved in the study published today.
“I am really optimistic,” Wieden said. “I hope that this will be literally a missing link that could just change the lives of people with MS.”
Scanlan originally developed sobetirome as a synthetic molecule more than two decades ago, initially with an eye toward using it to lower cholesterol. In recent years, Scanlan’s lab adapted it as a promising treatment for a rare metabolic disease called adrenoleukodystrophy, or ALD.
Six years ago, Bourdette suggested trying the compound to repair myelin in MS.
Supported by funding provided through the Laura Fund and the National Multiple Sclerosis Society, the team turned to Ben Emery, Ph.D., an associate professor of neurology in the OHSU School of Medicine. Emery, an expert who previously established his own lab in Australia focused on the molecular basis of myelination, genetically engineered a mouse model to test the treatment.
A ‘Trojan horse’
With promising early results, researchers wanted to see if they could increase the amount of sobetirome that penetrated into the central nervous system.
They did so through a clever trick of chemistry known as a prodrug strategy.
Scientists added a chemical tag to the original sobetirome molecule, creating an inert compound called Sob-AM2. The tag’s main purpose is to eliminate a negative charge that prevents sobetirome from efficiently penetrating the blood-brain barrier. Once Sob-AM2 slips past the barrier and reaches the brain, it encounters a particular type of brain enzyme that cleaves the tag and converts Sob-AM2 back into sobetirome.
“It’s a Trojan horse type of thing,” Scanlan said.
Researchers found that the treatment in mice not only triggered myelin repair, but they also measured substantial motor improvements in mice treated with the compound.
“The mouse showed close to a full recovery,” Scanlan said.
Scientists say they are confident that the compound will translate from mice to people. To that end, OHSU has licensed the technology to Llama Therapeutics Inc., a biotechnology company in San Carlos, California. Llama is working to advance these molecules toward human clinical trials in MS and other diseases.
Bourdette said even though it may not help his patients today, he’s optimistic the discovery eventually will move from the lab into the clinic.
“Right now, what it means is hope,” he said.
Learn more: Study shows promise in repairing damaged myelin
The Latest on: Myelin repair
via Google News
The Latest on: Myelin repair
- National MS Society Commits $14.6 Million to 43 New Research Projects to Support Breakthroughs for Multiple Sclerosison October 16, 2019 at 11:10 am
These projects include new strategies to treat progressive MS, the role of diet and gut bacteria, and novel approaches to repair myelin. NEW YORK, Oct. 16, 2019 /PRNewswire-PRWeb/ -- Projects include ...
- Blocking LRP1 May Halt Inflammation, Promote Remyelination, Mouse Study Suggestson October 10, 2019 at 5:20 am
Blocking production of the low-density lipoprotein receptor-related protein 1 (LRP1) — involved in inflammatory and immune responses — specifically in myelin repair cells halts ...
- We can stop multiple sclerosis, and this is howon October 9, 2019 at 5:40 am
Finding treatments that can regenerate myelin has eluded scientists for decades – it has been the major missing piece of the MS treatment puzzle. The UK is a world leader in this kind of research and ...
- What exactly is MS and is there a cure?on October 8, 2019 at 11:17 am
‘But they continued to discover other, more powerful drugs. Now we have a wide range of life-changing DMTs to offer.’ Another vital area of research is myelin repair – looking at ways to regenerate ...
- Surprise contributor to multiple sclerosison October 7, 2019 at 9:22 am
The good news: The new insights into the progenitor cells suggest that doctors could potentially manipulate the environment inside the brain to avoid neurodegeneration and promote brain repair. In the ...
- Team discovers surprise contributor to multiple sclerosison October 7, 2019 at 9:20 am
... that doctors could potentially manipulate the environment inside the brain to avoid neurodegeneration and promote brain repair. In the lab, blocking the effects of the cells reduced inflammation ...
- Diabetes drug could halt progression of multiple sclerosis, study suggestson October 6, 2019 at 9:31 am
There are treatments for the early stages of MS, which modulate the immune system, but nothing helps people with the more advanced phase. This is the one of the most significant advances in myelin ...
- Type 2 diabetes drug could offer hope for multiple sclerosis after a study on ratson October 4, 2019 at 2:04 am
A type 2 diabetes drug can repair nerve damage caused by multiple sclerosis (MS), according to trials on rats. Cambridge University scientists gave rodents the blood sugar-lowering medication ...
- Diabetes drug offers hope of new treatment for multiple sclerosison October 2, 2019 at 8:09 am
If this relatively simple, cheap and available drug can rejuvenate myelin repair in humans as well, then this may be really helpful in neurodegenerative diseases such as multiple sclerosis where ...
- The Neural Androgen Receptoron September 28, 2019 at 5:00 pm
The stimulation of endogenous myelin repair remains an important therapeutic challenge in multiple sclerosis. Under conditions of severe and chronic demyelination, we found that testosterone is a ...
via Bing News